Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis - Cardiovascular Diabetology
Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-023-01756-0
Background The novel sodium-glucose co-transporter 2 inhibitor (SGLT2i) potentially ameliorates heart failure and reduces cardiac arrhythmia. Cardiac fibrosis plays a pivotal role in the pathophysiology of HF and atrial myopathy,...
Conclusions: By inhibiting NHE, empagliflozin decreases the expression of phosphorylated PLC and IP3 production, thereby reducing ER Ca2 release, extracellular Ca2 entry and the profibrotic activities of atrial fibroblasts.
Share
Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy
Hyperfiltration is the driving force that leads nephrons to glomerulosclerosis and eventually results in chronic kidney disease (CKD) and end-stage kidney disease (ESKD). It has therefore been intuitive that decreasing...
Conclusion: Empagliflozin is the latest SGLT2i drug to show proven benefits in both hyperglycemia, CV disease, heart failure, and now CKD progression. The new EMPA-KIDNEY data proves that it provides benefits in patients with and without diabetes and can be used in those with eGFR down to 20 mL/min/1.73m2. The medication is further solidified...
Share
Conclusions and Relevance: In this study, among patients with HFpEF and pacemakers, treatment with a moderately accelerated, personalized pacing rate was safe and improved quality of life, NT-proBNP levels, physical activity, and atrial fibrillation compared with the usual 60 bpm setting.
Share
Postop Complication With Euglycemic Diabetic Ketoacidosis in a Patient Receiving Empagliflozin
Euglycemic diabetic ketoacidosis (EDKA) is an uncommon diabetic complication with increasing prevalence and is associated with the use of sodium-glucose co-transporter 2 inhibitors (SGLT2i). We report the case of a...
#!/
Conclusions: Patients treated with SGLT2i presenting with prostration and elevated anion gap metabolic acidosis should be tested for the presence of ketones. The early recognition of risk factors in patients under SGLT2i allows the prevention and treatment initiation of EDKA. Standard guidelines should be developed to help physicians in...
Share
Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure with Preserved Ejection Fraction: Proposed Mechanisms, Recent Evidence, and Clinical Implications - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36728757/
Heart failure (HF) affects approximately 6 million Americans and is projected to increase in prevalence as the population ages. While progress has been made in the treatment of heart failure...
Conclusions/Relevance: While trials of empagliflozin for HFpEF did not show a mortality benefit, sodium-glucose co-transporter 2 inhibitors are promising additions to the management of HFpEF for their effects on the disease's risk factors through weight loss, natriuresis, blood pressure lowering, and glycemic control.
Share